Non-Hodgkin Lymphoma by Clinical Course

Non-Hodgkin Lymphoma by Clinical Course — Trials · CancerIndex

Clinical trials

Registered studies

1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 172
Ph III recruiting: 8
Growth YoY: +32.7%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (209)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04052854	A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies	no longer available	—	—	BeiGeneINDUSTRY	1	Oct 23, 2024	clinicaltrials
NCT05131438	An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)	no longer available	—	—	EQRx International, Inc.INDUSTRY	1	Mar 27, 2023